Brazil received 9,800 doses of immunity from Jyneos/MVA-BN last Wednesday (October 4, 2022)
The research aims to monitor evidence of the efficacy, immunogenicity, and safety of the vaccine against the disease. Recommendation from the World Health Organization (WHO).
The studies will be funded by Fiocruz (Fundação Oswaldo Cruz) and the Ministry of Health, with support from the World Health Organization. The research has been discussed by the Brazilian authorities with the Pan American Health Organization and researchers and experts in the field.
The target audience includes people exposed to the virus, that is, those who have had prolonged contact with an infected patient and pre-exposure individuals, who are on pre-exposure prophylaxis (PrEP) or who are on antiretroviral therapy for HIV.
Health professionals are not in the vaccination priority group. According to the Ministry of Health, epidemiological data for this group in Brazil and in the world do not show a greater exposure to the disease, as they collect and care for patients with individual protective equipment (PPE). In the case of prolonged and unprotected contact with a confirmed case, a specialist may be assigned to receive the vaccine.
In total, the federal government has purchased about 50,000 doses of the vaccine against monkey pox. The next batches should be delivered by the end of 2022. The vaccines were obtained through a revolving fund of the Pan American Health Organization (PAHO).
Although the vaccines were initially intended to conduct studies, the ministry confirmed that the vaccines are safe and are currently used against smallpox.
Since May, the world has seen the largest outbreak of the virus outside Africa.
a 360 . force Prepare a report explaining monkeypox. Read symptoms, transmission methods, prevention and treatment:
“Wannabe internet buff. Future teen idol. Hardcore zombie guru. Gamer. Avid creator. Entrepreneur. Bacon ninja.”